The London Biotech Network

The London Biotech Network was established in 2000 by London First. Now co-sponsored by the London Development Agency, LBN has over 2,500 individual members from 800 organisations. The aim of LBN is to create effective communication networks and business forums that allow the wide range of companies and institutions in the life sciences arena to benefit from London’s unique offerings – the enormous biomedical research cluster, the expert professional services sector and the most international stock exchange in the world.

Key facts about London’s Biotechnology Sector

• Over 100 biotechnology companies – including Antisoma, Trigen, Arrow, Inpharmatica - employing around 6000 staff.
• 28 universities and higher educational institutes employing 1300 researchers in biomedical research
• Five internationally renowned medical schools
• More biotechnology venture capital groups than the top ten other European cities combined
• A patient population of 7.2 million growing to 9 million including commuters
• Home to London Stock Exchange, including AIM, turning over £300 million per day
• 98 hospitals, 75 of which are NHS Trusts attracting nearly £300 million in annual R&D revenue
• More than 50 clinical research organisations and hospitals make London the leading centre in Europe for clinical trials
• London is home to key regulatory and industry bodies such as the EMEA, MHRA, ABPI and BIA